Chapter 28: Drugs for Muscle Spasm and Spasticity

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement, not replace the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Usually a seizing muscle feels like a tangled slinky.

It's just the simple localized hardware issue.

Right, like a cramp.

Yeah, exactly.

You apply some heat, maybe massage it out and the muscle just releases.

But if you were staring down chapter 28 of Lane's pharmacology for nursing care, you know that a tangled slinky might actually be a symptom of a massive neurological short circuit.

Oh, absolutely.

It gets a lot more complicated.

It really does.

So today, our mission on this deep dive is to take this really dense pharmacology text, focusing exclusively on chapter 28 and translate these drug classes into like plain student -friendly language.

Which is so needed.

For sure.

For you, the college nursing student who is seeing this for the first time and staring down a massive exam, we are going to decode the therapeutic goals, the mechanisms of action, and well, the clinical implications.

So the reasoning behind your safe medication decisions is incredibly easy to follow.

Okay, let's unpack this.

We really need to start with the absolute core lesson of this chapter.

As a future nurse, your foundational understanding must be that we are, we're dealing with two completely different physical problems here.

On one side, we have localized muscle spasm, and then on the other side, we have spasticity.

The cardinal rule of chapter 28 is that the drugs used to treat these two conditions are not interchangeable.

Wait, not at all.

Well, with one notable exception that we'll cover later, but generally no.

Drugs for spasticity do not work for localized spasm and vice versa.

And I mean, that completely makes sense when you look at where these problems actually come from.

Spasticity is a group of movement disorders that originate in the central nervous system, the CNS.

Exactly.

We are talking about severe conditions like multiple sclerosis, cerebral palsy,

traumatic spinal cord lesions, and stroke.

Spasticity is characterized by heightened muscle tone, intense spasms, and a pretty profound loss of dexterity.

Yeah, the origin is entirely neurological.

Contrast that with a localized muscle spasm, which is an involuntary contraction that stems from acute musculoskeletal injury or trauma.

Like a gym injury.

Right.

Think of the patient who just pulled a muscle trying to lift a heavy couch.

That is an acute localized tissue issue.

It's not a chronic CNS disorder.

So mixing up the pharmacological treatments for these two distinct problems won't just fail to help your patient, it can actively cause harm.

Wow, okay.

So since spasticity originates in the CNS, the physiological logic kind of dictates that we start our treatment by targeting the CNS directly.

That's the exact right approach.

Which brings us to our first prototype drug for spasticity, baclofen.

Baclofen is the classic prototype for centrally acting muscle relaxers.

To understand how it works, you have to understand its mechanism of action, or MOA.

Right.

Baclofen acts directly within the spinal cord to suppress the hyperactive reflexes that regulate muscle movement.

Physiologically, it's a structural analog of the inhibitory neurotransmitter GABA.

Gamma -am immunobutyric acid, right.

Exactly.

GABA is essentially the nervous system's primary brake pedal.

By mimicking GABA on spinal neurons, baclofen binds to those receptors and just dampens those chaotic hyperactive signals firing down the spinal cord.

So it's basically like noise canceling headphones for the spinal cord.

I love that analogy.

Like it turns down the volume dial at the spinal cord receiver, but it doesn't unplug the muscle speaker wire.

The muscle still works perfectly fine, but baclofen blocks out the hyperactive static coming from the damaged central nervous system.

That's a great way to put it.

But wait, I do have a question about that mechanism.

If baclofen is pressing the nervous system's brake pedal and dampening motor signals, why doesn't the patient just go entirely limp?

How do they maintain any strength at all?

That is the exact clinical advantage of baclofen.

You have to differentiate between hyperactive reflex signals and intrinsic muscle power.

Baclofen has absolutely no direct muscle relaxant action on the skeletal muscle fibers themselves.

None.

It purely targets the misfiring reflexes in the spinal cord.

Because it leaves the actual muscle fibers alone, it does not decrease the patient's intrinsic muscle strength.

You get the relief from the rigidity and spasticity without turning the patient's limbs to jelly.

I mean, that is a massive benefit for a patient trying to maintain mobility.

It really is.

But we need to look at the indications carefully.

Baclofen is highly effective and approved for conditions like MS and spinal cord injuries.

But the text explicitly states what it is not approved for.

Right, you have to know the exclusion.

You cannot use baclofen for spasticity related to cerebral palsy, stroke, Parkinson's disease, or Huntington's Korea.

What's fascinating here is the trade -off.

Even though it doesn't weaken the muscles, baclofen is a CNS depressant.

Mimicking GABA means slowing things down globally.

Right, the whole system.

Yeah.

So in the early phases of therapy, your patient is going to experience drowsiness, dizziness, weakness, and fatigue.

It also slows down the gastrointestinal and genitourinary tracts.

Which causes issues like nausea, constipation, and urinary retention, right?

Exactly, you'll see those a lot.

We also have to address the severe risks because this isn't a drug you can just take lightly.

An overdose of baclofen can produce profound coma and respiratory depression.

It's very dangerous.

And the scariest part for a nurse, there is no known antidote.

If your patient overdoses, treatment is purely supportive, just maintaining an airway and riding it out.

Which leads directly to the massive safety alert regarding withdrawal.

You cannot just abruptly stop baclofen.

Never.

If a patient abruptly withdraws from oral baclofen,

the sudden absence of that inhibitory brake pedal causes the nervous system to rebound in a state of hyper -excitability.

They can experience visual hallucinations, paranoid ideation, and severe seizures.

It sounds terrifying.

It is.

But if we pull from table 28 .1 and look at the clinical administration tools, the stakes get astronomically higher when we talk about intrathecological dosing.

Right, intrathecological administration.

This is when the drug is delivered via a surgically implanted, programmed pump directly into the spinal fluid.

The dosing difference is wild.

It's a huge difference.

Oral baclofen is dosed in milligrams, maybe 15 to 20 milligrams a few times a day, but intrathecological baclofen is dosed in micrograms.

Because it is being delivered directly into the cerebrospinal fluid, bypassing the bloodstream entirely, it is incredibly potent.

And if that intrathecological pump fails or the drug runs out and is abruptly withdrawn, the clinical cascade is life -threatening.

The patient rapidly develops a high fever, altered mental status, and an exaggerated rebound spasticity.

It escalates so quickly.

Yeah, that violent muscle rigidity can progress into rhabdomyolysis, which is the severe breakdown of muscle tissue.

As those muscle fibers die, they spill massive proteins into the blood, clogging the kidneys, leading to multiple organ system failure and death.

This is a textbook example of why the nursing implications stressed absolute vigilance.

The infusion system must be programmed perfectly, monitored constantly, and patient education about keeping their refill appointments is literally a matter of life and death.

But here is the limitation of baclofen.

You're relying on the spinal cord to receive the drug.

What if the neurological signaling pathway is so damaged that working centrally just isn't an option?

That happens.

Or what if we need to hit the muscle directly?

That shifts our focus from the central approach to the direct approach, leading us to our next prototype drug, dantrolene.

Dantrolene is highly unique in this chapter.

It is the only direct acting muscle relaxer we use for spasticity.

The only one.

The only one.

Instead of mimicking GABA in the spinal cord, dantrolene bypasses the nervous system entirely and works right inside the skeletal muscle cell.

To understand how, you have to look at the sarcoplasmic reticulum.

Okay, bringing back anatomy.

Normally for a muscle to contract, the sarcoplasmic reticulum releases calcium into the cell.

Calcium is basically the key in the ignition for muscle fibers to slide together.

Dantrolene works by suppressing that release of calcium.

Okay, I have to push back on this.

If dantrolene literally locks up the calcium and stops the muscle fibers from contracting forcefully, doesn't that just make the patient physically weak overall?

It does.

How is that actually helpful to their daily functioning?

That is the exact clinical dilemma you will face at the bedside.

Yes, because dantrolene causes a generalized reduction in the ability of skeletal muscle to contract, it is absolutely associated with a significant reduction in strength.

Wow, okay.

This is where person -centered care is vital.

Imagine a patient with multiple sclerosis who relies on a certain degree of rigid spasticity in their legs just to lock their knees and stand upright.

Like using the spasticity as a crutch.

Exactly.

If you give them dantrolene and take away that spasticity, you might actually take away their ability to walk.

The nurse must carefully evaluate whether the benefit of reduced pain and spasms genuinely outweighs the harm of generalized muscle weakness for that specific patient.

That makes perfect sense.

You're treating the patient's function, not just their symptoms.

Now, dantrolene is indicated for MS, cerebral palsy, and spinal cord injuries, but there is a crucial addition in the text.

Dantrolene is also the primary treatment for malignant hyperthermia.

Yes, that is a huge point to remember.

Malignant hyperthermia is a rare, terrifying, life -threatening syndrome triggered by certain general anesthetics.

The muscles go into massive uncontrolled rigidity, generating lethal amounts of body heat.

By stopping that calcium release directly at the muscle, dantrolene halts the metabolic chain reaction.

While it's a lifesaver in the operating room for routine daily spasticity management, dantrolene carries a severe black box warning for dose -related hepatic toxicity.

Liver damage is the main concern.

Yeah, the text states that liver damage is the most serious adverse effect, with an incidence of one in 1 ,000 patients, and it can actually be fatal.

And it specifically points out that this hepatotoxicity is most common in women over the age of 35.

Because of this severe risk, baseline and periodic liver function tests, or LFTs, are mandatory.

You really have to track it.

Absolutely.

This is why you don't just hand over this medication and wave goodbye.

If your patient comes in a week later complaining of right upper quadrant abdominal pain, or you notice their sclera looking slightly yellow, your mind has to immediately go to hepatotoxicity.

We also need to talk about the administration implications.

Intravenous dantrolene is a vesicant.

That's critical for IV care.

Right.

For a nursing student, you need to understand that a vesicant is a chemical that causes severe blistering tissue injury if it escapes the vein.

If that IV line slips and dantrolene seeps into the surrounding subcutaneous tissue, the necrosis can be devastating.

Care must be taken to ensure a perfectly patent IV line.

Beyond that, about a third of patients receiving IV dantrolene will experience a significant flushing reaction.

And for patients taking it orally at home, they need to know it causes severe photofensitivity.

Sunburns, right?

Yeah, the skin becomes highly reactive to UV light, meaning they can get terrible blistering sunburns if they aren't careful.

Okay, so we've spent a lot of time on chronic CNS disorders with baclofen and dantrolene, but let's shift gears completely.

Let's talk about the patient who was perfectly fine yesterday but pulled a muscle deadlifting at the gym.

We're leaving spasticity behind and moving to acute localized muscle spasm.

For acute localized spasms, the textbook emphasizes that the first line of defense is actually non -drug therapy.

Like stretching.

Exactly.

We're talking about physical therapy, specific stretching exercises, whirlpool baths, and local heat application.

Pharmacologically, you start with simple analgesics like acetaminophen or NSAIs.

Do the counter stuff.

Right.

But when the pain and spasm are too severe, we bring in the centrally acting muscle relaxants with cyclobenzeprine as our prototype.

Here's where it gets really interesting.

If you read the adverse effect profile for cyclobenzeprine, it feels contradictory.

Well, the text says its mechanism of action is primarily up in the brainstem, reducing tonic motor activity.

But wait, if this drug is working in the brainstem to relax a motor signal, why is my patient suddenly complaining about a dry mouth, blurred vision, and the inability to pee?

I see what you mean.

These are classic anticholinergic side effects.

Why are they happening if it's working on motor signals?

It all comes down to the drug's molecular chemistry.

Cyclobenzeprine is structurally very similar to tricyclic antidepressants, or TCAs.

Well, that makes sense.

Yeah.

Because of that specific structural similarity, it carries potent anticholinergic effects, just like those older psychiatric drugs do.

It blocks acetylcholine receptors globally.

It also means it can cause cardiac rhythm disturbances, including sinus tachycardia and significant conduction delays.

That structural similarity is also the exact reason for a massive safety alert box in this chapter regarding serotonin syndrome.

Yes, do not skip that box.

Cyclobenzeprine is absolutely contraindicated for patients taking monoamine oxidase inhibitors, or MAOIs.

A patient must be off MAOIs for a full two weeks before starting cyclobenzeprine.

If they aren't, the combination causes an excessive accumulation of serotonin in the brain, triggering fatal serotonin syndrome.

And it's not just MAOIs.

It is highly dangerous to combine cyclobenzeprine with SSRIs, SNRIs, other tricyclic antidepressants, and even tramadol.

This makes your patient teaching vital.

You can't just tell a patient to watch out for side effects.

You have to delineate the manifestations of serotonin syndrome so they know what an emergency looks like.

You have to be specific.

Right.

You are teaching them to watch for central nervous system changes, like extreme agitation and confusion, autonomic signs, like spiking a sudden fever or a wildly rapid heart rate, and neuromuscular issues like tremors, hyperreflexia, and involuntary muscle twitching.

And on the milder day -to -day side, for those annoying anticholinergic effects we mentioned, you teach the patient actionable steps.

Tell them to chew sugar -free gum or sip water constantly to combat the dry mouth.

Explain that their pupils might dilate, which causes photophobia, so they should wear sunglasses outside.

Now, cyclobenzeprine is considered the most efficacious drug for acute muscle spasm, making it the clear first choice.

But to reiterate our pardonal rule, it is completely ineffective for spasticity.

If we connect this to the bigger picture,

cyclobenzeprine isn't the only option for localized spasms.

We need to look at the rest of this centrally acting class, which includes diazepam, tizanidine, carosaprodol,

clozoxazone, metaxalone, methocarbamol, and orphanadrine.

That's quite a list.

It is, and the text makes a crucial point here.

For most of these other drugs, the mechanism of action is actually somewhat unclear.

Right.

Many researchers believe that the relief from localized muscle spasm primarily comes from the powerful sedative properties of these drugs, rather than any specific targeted action on the CNS pathways that control muscle tone.

Yeah, it's mostly sedation.

Basically, the drug sedates the patient's entire nervous system so heavily that the tense muscle finally just gives up and relaxes.

Exactly.

But there are a couple with specific known MOAs.

Diazepam, which is a benzodiazepine, works by enhancing the effects of GABA, just like baclofen does, but at different receptor sites.

Tizanidine acts as an agonist at presynaptic alpha -2 receptors, reducing the release of excitatory neurotransmitters.

Diazepam is special here, right?

Yes, and you have to highlight diazepam here.

It is the only drug in this entire chapter approved to treat both spasticity and localized muscle spasm.

While all these drugs cause generalized CNS depression, there are specific, sometimes dangerous adverse effects tied to individual drugs in this group that a nursing student absolutely must memorize.

Let's pull some of those memorable details out of the text.

We already know dantrolene causes liver toxicity, but in this group, tizanidine and metaxalone are also hepatotoxic.

But chlorzoxazone is the real stand -up for liver danger.

It can cause potentially fatal hepatic necrosis.

Literally the death of liver tissue.

Yeah.

The textbook explicitly states that because of this extreme risk and because other drugs work just as well, the risk of using chlorzoxazone generally exceeds its benefits.

We also have to monitor for physical dependence.

Chronic high -dose therapy with these CNS depressants alters the brain's chemistry.

If you abruptly withdraw them, it can lead to a life -threatening abstinence syndrome.

You have to taper them.

Specifically, diazepam and carisoprotal are schedule V controlled substances due to their significant potential for abuse and physical dependence.

Now, let's talk about the side effects that are completely harmless, but will absolutely terrify a patient if you don't explain the why beforehand.

Oh, I love these quirks.

When drugs break down in the liver, they form metabolites that are excreted in the urine.

For some of these drugs, those metabolites are highly pigmented.

Methocarbamol metabolites can turn a patient's urine brown, black, or dark green.

Chlorzoxazone metabolites can turn urine orange or purple red.

Imagine seeing that with no warning.

As a nurse, imagine your patient goes to the bathroom and sees dark green or purple urine.

If you didn't proactively teach them that this is a harmless, expected chemical reaction, they are going to panic and think their kidneys are failing.

We also need to translate the administrative details hidden in tables 28 .1 and 28 .2 into vivid clinical practice.

For example, bioavailability.

How much of the drug actually reaches systemic circulation?

Food plays a big role there.

Yeah, taking cyclobenzaprine, metaxalone, or tizanidine with food actually increases their bioavailability.

So you want to instruct patients to be consistent with taking it with meals.

Or look at intravenous administration.

If you administer methocarbamol intravenously, it can cause sudden, severe hypotension.

If you let that patient stand up right after pushing the IV, they will pass out and hit the floor.

It drops the blood pressure too fast.

The text states the patient must stay lying down for 10 to 15 minutes post -IV to allow their blood pressure to stabilize.

And think about extended release capsules like ER -cyclobenzaprine.

Imagine you have a patient who cannot swallow pills.

It is incredibly tempting to just crush that capsule to make it easier for them.

Oh, you definitely can't do that.

Right, but if you do that, you destroy the slow release matrix.

You are suddenly hitting that patient with a massive, immediate dose of a CNS depressant, leading to instant toxicity.

So what's the alternative?

You can open the capsule and sprinkle the intact beads on applesauce, but they must never be chewed.

These administration details tie directly into lifespan considerations.

The text is very strict about age demographics.

You cannot give chlorzoxazone, orphanadrine, or tizanidine to children.

Their safety is simply not established.

And pregnancy is a major factor.

Right, diazepam is highly dangerous in pregnancy as it's associated with low birth weights, neonatal withdrawal syndrome, and developmental defects.

But the most heavily emphasized lifespan demographic is the older adult population.

These centrally acting relaxants are heavily featured in the BEERS criteria, a list of medications considered potentially inappropriate for older adults.

Mostly because of the sedation.

Yes, at the dosages required to relieve a spasm, these drugs cause severe sedation, cognitive impairment, and dizziness.

In a frail older adult, that creates a massive, unacceptable fall risk.

And diazepam is especially troublesome.

Older adults naturally have slower hepatic metabolism and renal excretion.

So it just builds up.

Exactly.

The elimination of diazepam is significantly delayed.

So instead of clearing the drug, the active metabolites just accumulate in their system day after day, making the sedation worse and worse over time.

Which brings us to synthesizing your overarching nursing responsibilities across all these medications.

No matter which of these drugs you are pulling from the plexus, you must assess the patient's baseline spasm, rigidity, and range of motion before administration so you know if the drug is actually working.

You have to know the baseline.

You are constantly monitoring for profound CNS depression, meaning you aggressively advise your patients against driving or combining these drugs with alcohol or other depressants like opioids.

You must establish baseline and periodic liver function tests.

And you must remember the golden rule of central agents like baclofen.

Never ever abruptly withdraw them.

So what does this all mean?

For you, the nursing student getting ready to sit down for this exam, the main takeaway is this.

Knowing the distinct physiological boundaries between spasticity drugs and spasm drugs is the absolute key to safe medication decisions.

It's the whole foundation.

You have to know your prototypes.

Baclofen for central spasticity, dantrolene for direct spasticity, and ancilbenzoprene for acute localized spasm.

You mix those indications up or you confuse a milligram oral pill with a microgram intracycle spinal pump and you are putting your patient in direct danger.

This raises an important question, something for you to reflect on as you move from reading textbook chapters into actual clinical practice.

We've seen how drugs like dantrolene can effectively relieve spasticity by locking up calcium, but at the cost of causing generalized muscle weakness.

The trade -off.

Yes.

As a future nurse,

how will you navigate the complex clinical balance of taking away a patient's painful spasticity if it means simultaneously taking away the rigid muscle tone they currently rely on to stand up, transfer, and function?

It's a powerful thought because it reminds us that we are treating a whole complex human being, not just a tangled slinky.

The diagnostic and pharmacological waters might be incredibly dense, but by understanding the why and the how behind these mechanisms, you know how to navigate them safely.

From the Last Minute Lecture Team, thank you so much for joining us on this deep dive.

Study hard, trust your knowledge, and remember, you've got this exam in the bag.